<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8114">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755104</url>
  </required_header>
  <id_info>
    <org_study_id>RCM-EFF-1</org_study_id>
    <nct_id>NCT01755104</nct_id>
  </id_info>
  <brief_title>Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome</brief_title>
  <official_title>A Randomized Double-blind Placebo Controlled Trial on the Effect of Stablor™ on the Abdominal Visceral Fat Mass Loss in Patients With a Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Nutrition et Cardiometabolisme</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Nutrition et Cardiometabolisme</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the impact of the intake of a dietary supplement
      STABLOR™ on the change of the abdominal visceral fat mass in patients with a metabolic
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in visceral fat area assessed by computerized tomodensitometry</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in selected cardiometabolic risk factors : anthropometric and physical measurements, biomarkers</measure>
    <time_frame>from baseline to end of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, psychological and behavioral changes</measure>
    <time_frame>From baseline to end of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Stablor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement Stablor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dietary supplement Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stablor</intervention_name>
    <arm_group_label>Stablor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With a Body Mass Index (BMI) more than or equal to 25 kg/m² and less than 40 kg/m²,

          -  With a metabolic syndrome characterized by a a waist circumference of more than 94 cm
             for the males (90 cm for South-Asians, Chinese and Japanese) and more than 80 cm for
             the females, and at least 2 of the following criteria :

               -  Arterial Blood pressure &gt; or = 130 mmHg (systolic) and/or more than or equal to
                  85 mmHg (diastolic) or stabilized with treatment for at least 6 months,

               -  Fasting glycemia &gt; or = 1 g/L or 5.6 mmol/L or  stabilized with treatment for at
                  least 6 months and non-diabetic &lt; 1.26 g/L,

               -  Triglycerides &gt; or = 1.5 g/L or 1.71 mmol/L or  stabilized with treatment for at
                  least 6 months,

               -  HDL Cholesterol &lt;0.40 g/L or 1.03 mmol/L (males) and  &lt;0,5 g/l or 1.29 mmol/L
                  (females) or  stabilized with treatment for at least 6 months.

        Exclusion Criteria:

          -  Pregnant (positive pregnancy test at the selection visit or breast-feeding woman,

          -  Woman of childbearing potential without an efficient contraception method,

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in the clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Clement, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut CardioMetabolisme et Nutrition (ICAN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut CardioMetabolisme et Nutrition (ICAN)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
